Altitude Lab, a biotech accelerator based in Salt Lake City, Utah, has announced the launch of its pre-seed venture fund.

The new initiative is designed to support early-stage biotechnology startups that have been affected by recent shifts in federal funding policies.

Supporting Early-Stage Biotech Startups

The Altitude Lab Fund seeks to help small, innovative biotech companies that have been reviewed under the Small Business Innovation Research (SBIR) program.

The fund aims to provide not only financial support but also valuable resources to these startups, strengthening Salt Lake City’s position as a growing national biotech hub.

What the Fund Offers

Startups selected for the Altitude Lab Fund will receive:

Pre-seed investment capital ranging from $100,000 to $250,000
12 months of lab and office space
Access to Altitude Lab’s competitive accelerator program, which includes mentorship from leading industry executives and opportunities to connect with top-tier national funds

Leadership Behind the Fund

The fund will be led by Chris Gibson, Co-founder and CEO of Recursion, along with serial entrepreneur David Bearss and Altitude Lab’s executive director Chandana Haque.

Together, they bring their expertise and vision to support the next generation of biotech innovators.

With this new initiative, Altitude Lab is helping to build a vibrant ecosystem for biotech companies, providing the resources and guidance needed to fuel growth and innovation in the field.

This article was published on TDPel Media. Thanks for reading!

Share on Facebook «||» Share on Twitter «||» Share on Reddit «||» Share on LinkedIn